Gene expression signatures to predict the development of metastasis in breast cancer.

Understanding and preventing the development of distant metastases is the most important aim in research and treatment of malignant tumors, including breast cancer. In patients with primary breast cancer without lymph node metastases who are under 50 years of age, approximately 25% will develop distant metastases after 5 years. When treated with adjuvant chemotherapy, this can be reduced to approximately 18%. When lymph node metastases are present at primary treatment, approximately 50% of the patients will develop distant metastases and this figure can be reduced to less than 40% by adjuvant chemotherapy treatment. In elderly women (50-69 years) the benefit of chemotherapy decreases from approximately 10% absolute benefit to 5% absolute benefit [1]. These numbers illustrate on the one hand the benefit for adjuvant chemotherapy, on the other hand that a large number of patients will also remain free of recurrence without adjuvant chemotherapy and suffer from the site effects without any benefit from the toxic treatment. It will be of great clinical benefit to be able to better predict which tumors will develop distant metastases, as adjuvant systemic treatment can than be better tailored to individual patients. In addition, identification of such predictive factors for distant metastases will lead to more insight in the biological processes leading to the development of distant metastases.

[1]  Christine Desmedt,et al.  Proliferation: the Most Prominent Predictor of Clinical Outcome in Breast Cancer , 2006, Cell cycle.

[2]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[3]  A. Nobel,et al.  Concordance among gene-expression-based predictors for breast cancer. , 2006, The New England journal of medicine.

[4]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[7]  Howard Y. Chang,et al.  Genetic regulators of large-scale transcriptional signatures in cancer , 2006, Nature Genetics.

[8]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[9]  Trevor Hastie,et al.  Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers , 2006, PLoS medicine.

[10]  C Sotiriou,et al.  Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Tina Hernandez-Boussard,et al.  Determination of Stromal Signatures in Breast Carcinoma , 2005, PLoS biology.

[12]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[13]  E. Liu.  Mechanism-derived gene expression signatures and predictive biomarkers in clinical oncology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[16]  Stefan Michiels,et al.  Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.

[17]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[18]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[19]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[20]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[21]  Ash A. Alizadeh,et al.  Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.

[22]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[25]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[26]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[27]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[29]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[32]  R. Tibshirani,et al.  Generalized Additive Models , 1986 .

[33]  David C. Atkins,et al.  Multi-center validation of the 76-gene prognostic signature in lymph node negative (LNN) primary breast cancer , 2005 .

[34]  D. Botstein,et al.  The transcriptional program in the response of human fibroblasts to serum. , 1999, Science.